| HDACI |
Study |
Phase |
Identifier Number |
| Entinostat (SNDX-275) |
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer |
II |
NCT01349959 |
| Entinostat |
Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic |
III |
NCT02115282 |
| Entinostat |
Entinostat, LapatinibDitosylate and Trastuzumab in Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only |
I |
NCT01434303 |
| Panobinostat (LBH589) |
Re-expression of Estrogen Receptor (ER) in Triple Negative Breast Cancers |
I/II |
NCT01194908 |
| Vorinostat |
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy |
Pilot |
NCT01720602 |
| Vorinostat |
Vorinostat, Paclitaxel, and Bevacizumab in Treating Patients With Metastatic Breast Cancer and/or Breast Cancer That Has Recurred in the Chest Wall and Cannot be Removed by Surgery |
I/II |
NCT00368875 |
| Vorinostat |
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer |
I |
NCT01084057 |
